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Abstract
Background: The prognostic value of heart failure specific and global health status before and after left ventricular
assist device (LVAD) implantation in the usual care setting is not well studied.
Methods: We included 3,836 continuous-flow LVAD patients in the INTERMACS registry. Health status was measured
pre-operatively and 3 months post-LVAD using the Kansas City Cardiomyopathy Questionnaire (KCCQ) and EuroQol
visual analog scale (VAS). Primary outcomes were mortality/rehospitalization. Inverse propensity weighting was used to
minimize bias from missing data.
Results: Pre-operative global and heart failure-specific health status were very poor: KCCQ median 34.6 (IQR 21.4-50.5);
VAS median 43 (interquartile range (IQR) 25–65). Health status measures improved 3 months after LVAD placement:
KCCQ median 69.3 (IQR 54.2-82.3); VAS median 75 (IQR 60–85). Pre-operative health status was not associated with death
(unadjusted HR for lowest vs. highest score quartiles: 1.09 (0.85-1.41) KCCQ; 1.12 (0.85-1.49) VAS) or rehospitalization
(unadjusted HR 0.83 (0.72-0.96) KCCQ; 0.99 (0.85-1.16) VAS). Three-month KCCQ was associated with mortality
(unadjusted HR 2.17 (1.47-3.21); VAS was not (1.43 (0.94-2.17). Three-month KCCQ added incremental discriminatory
value to the HeartMate II Risk Score for death (c-stat 0.60 to 0.66); VAS did not (c-stat 0.59 to 0.60). Three-month health
status was associated with rehospitalization (unadjusted HR 1.31 (1.15-1.57) KCCQ; 1.24 (1.05-1.46) VAS), but did not add
incremental discriminatory value (c-stat 0.52 to 0.55 and 0.54, respectively).
Conclusions: These real-world data suggest that pre-operative health status has limited association with outcomes after
LVAD. However, persistently low health status after surgery may independently signal higher risk for subsequent death.
Further study is needed to determine the clinical utility of routinely collected health status data after LVAD implantation.
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Background
Although survival and adverse events following left ven-
tricular assist device (LVAD) placement have improved
over time, 2-year survival after LVAD remains at 70% in
the modern era [1]. Predicting mortality after LVAD is
challenging, with traditional risk models achieving a c-
statistic between 0.61-0.70 [2–4]. Accordingly, there are
few data to guide clinicians in patient selection for this
resource-intensive intervention, and current guidelines
rely heavily on expert opinion [5]. Furthermore, long-
term prognostication of patients who survive the acute,
post-surgical phase after LVAD placement is not well-
characterized. Therefore clinicians and patients often
make management and goals of care decisions based
upon personal, clinical and institutional experience.
One patient-reported measure that was initially hypoth-
esized to improve prognostication following LVAD is
health status. Health status encompasses symptom bur-
den, functional status, and quality of life, and is best
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captured by validated questionnaires [6]. Poor health sta-
tus is not only an important outcome to patients, but is
also a strong independent predictor of subsequent
hospitalization and mortality in patients with heart failure
[7–10] and those undergoing cardiac surgery [11–14].
However, these findings do not necessarily extend to pa-
tients undergoing LVAD implantation, as pre-operative
heart failure-specific health status was not associated with
mortality after LVAD in the clinical trial setting [15].
Based on these findings, it has been hypothesized that
heart failure treated with mechanical circulatory support
may represent a relatively unique clinical situation, dis-
tinct from heart failure and other cardiac surgeries, in
which the prognostic significance of health status may be
largely reversed due to the profound impact of LVAD on
the clinical course of the disease. However, while pre-
procedure health status may not be prognostic of long-
term outcomes after LVAD implantation due to a major
“resetting” of patients’ health status with treatment, post-
procedure health status may be associated with long-term
outcomes, and assist in the planning for further treatment.
Confirming these hypotheses in a contemporary, real-
world setting may identify health status not only as a
means for quantifying the benefits and risks of this treat-
ment, but also as a tool to help guide clinical decision-
making in the LVAD population.
To better characterize the association of pre- and
post-implant health status scores with outcomes following
LVAD in a usual care setting, we sought to build upon our
prior work through the following: 1) confirm that, outside
the clinical trial setting, pre-procedural health status was
not prognostic of subsequent mortality and rehospitaliza-
tion; 2) compare the relative strength of the association of
global, rather than disease-specific health status with out-
comes following LVAD; and 3) determine whether pa-
tients’ health status after the acute, post-surgical phase
was associated with subsequent survival and rehospitaliza-
tion. To address these goals, we leveraged a large, multi-
center North American observational registry to examine
the association between baseline and 3-month post-LVAD
global and disease-specific health status measures and
subsequent survival and rehospitalization.
Methods
Study design and population
Interagency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) is a prospective, quality-assurance
registry of de-identified data from all patients receiving a
Food and Drug Administration approved mechanical cir-
culatory support device at 165 participating centers.
Follow-up clinical data are collected after device implant-
ation at 1 week, 1 month, 3 months, 6 months, and
every 6 months thereafter. Health status data are col-
lected pre-operatively and at 3 and 6 months after
LVAD implantation and every 6 months thereafter.
Hospitalization and mortality outcomes are recorded
as they occur and at each follow-up period. All par-
ticipating sites obtained Institutional Review Board
(IRB) approval of the INTERMACS protocol. Individual
patient informed consent was obtained, when mandated
by the local IRB (some sites waived individual patient con-
sent as the INTERMACS registry was viewed primarily as
a quality improvement initiative). The current study did
not qualify as human subjects’ research because data were
de-identified and previously collected, therefore it was ex-
empt from Colorado Multiple Institutional Review Board
review. Enrollment in INTERMACS began in June 2006;
however, health status reporting was not emphasized until
May 2012. We therefore restricted our analysis to patients
enrolled in the INTERMACS database from May 2012 to
December 2013. We included all adult (≥19 years old) pa-
tients receiving a durable, continuous-flow LVAD. Base-
line analyses included all patients who had baseline health
status data available. Three-month analyses included only
patients who survived to 3 months and had 3-month
health status data available.
Health status measures
Heart failure-specific health status was measured using the
Kansas City Cardiomyopathy Questionnaire (KCCQ). The
KCCQ is a self-administered questionnaire that assesses
the domains of physical limitation, heart failure symptoms,
social limitation, self-efficacy, and health-related quality of
life. The validity, reliability, and responsiveness to change
in clinical status of the KCCQ have been previously re-
ported [16]. Answers to the questionnaire are converted
into a scale of 0 to 100, with lower scores indicating worse
health status. The overall summary score (OSS) was used
in these analyses, and represents an average of the physical
limitation, total symptoms, quality of life and social limita-
tion domains.
The EuroQol 5-Dimensions (EQ-5D) questionnaire is
a global health status measure that includes the Visual
Analog Scale (VAS) [17]. The VAS asks patients to rate
their overall health on a scale of 0 to 100, with 0 repre-
senting “worst imaginable health” and 100 indicating
“best imaginable health.” Given the more readily inter-
pretable data from the VAS and its proven association
with mortality [18] and peak VO2 [19] in patients with
heart failure, we used this scale as a measure of global
health status.
Statistical analysis
The distribution of KCCQ and VAS scores pre-LVAD
were heavily skewed towards poor values; therefore,
questionnaire answers were divided into score quartiles
rather than fixed ranges. Pre-operative characteristics
were compared using chi-square tests for categorical
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variables and one-way analysis of variance for continu-
ous variables.
Using the Kaplan-Meier method, we measured the raw
association between pre-operative and 3-month KCCQ
and VAS score quartiles with mortality and rehospitali-
zation after LVAD. Patients were censored at the time of
heart transplant, device explant or recovery. We assessed
the incremental prognostic value of baseline and 3-
month KCCQ and VAS scores in predicting both mor-
tality and rehospitalization when added to a base clinical
model using Cox proportional hazards models. To assess
whether the health status scores added prognostic infor-
mation to standard clinical risk factors, we first adjusted
for variables from the HeartMate II Risk Score (HMIIRS):
age, albumin, creatinine, INR, and center volume [20]. We
were not able to directly duplicate the HeartMate II Risk
Score as the INTERMACS registry reports age as a cat-
egorical variable (50–59 years, 60–69 years, etc.) to pro-
tect patient identity, and the center volume variable in the
HeartMate II Risk Score did not directly translate to the
INTERMACS registry setting. Therefore, we included all
of the Heartmate II Risk Score variables in a base Cox
model, with age entered as a categorical variable (by dec-
ade), center volume calculated as the average number of
INTERMACS-reported durable LVAD implants per year,
and albumin, creatinine and INR as continuous variables.
Inverse propensity weighting (IPW) was used to de-
crease the effect of selection bias due to missing health
status scores for both baseline and 3-month KCCQ and
VAS. First, the probability of having health status scores
available was calculated using a logistic regression
model. Then the inverse of the probability was assigned
to each patient with complete health status scores so
that patients who were most like those with missing
health status scores were given more weight, resulting in
an IPW model that is more reflective of the general
LVAD population included in the INTERMACS data-
base. These weighted estimates were used in all analyses.
IPW as a method for handling missing health status data
in the INTERAMCS database has been previously vali-
dated [21] and used by other investigators [22].
Analysis was performed using SAS version 9.3 (Cary,
NC). A two-sided p-value < 0.05 was considered significant.
Results
Pre-operative characteristics
The final cohort included 3,836 patients. Pre-operative
global and heart failure-specific health status were very
poor: VAS median 43 (interquartile range (IQR) 25–65);
KCCQ median 34.6 (IQR 21.4-50.5). Health status mea-
sures improved 3 months after LVAD placement: VAS
median 75 (IQR 60–85); KCCQ median 69.3 (IQR 54.2-
82.3). Table 1 displays baseline patient characteristics
stratified by pre-operative KCCQ score quartile. Patients
in the lowest KCCQ score quartile (indicating worse health
status) were more often female, INTERMACS profiles 1 or
2 at the time of device implant, and more frequently
required dialysis or intra-aortic balloon pump prior to im-
plant. Age group and implant strategy were not signifi-
cantly associated with baseline KCCQ score quartile.
Missing data
At baseline, 42% of patients were missing KCCQ, and
43% of patients were missing VAS. At 3 months, 41% of
patients were missing KCCQ, and 42% of patients were
missing VAS. However, nearly 1/3 of the patients miss-
ing either KCCQ or VAS at 3 months did not complete
any of the 3-month follow-up. Of patients who com-
pleted the 3-month follow-up, 34% and 35% of patients
were missing KCCQ and VAS, respectively. Baseline
KCCQ and VAS were most commonly missing due to pa-
tient and administrative reasons, whereas 3-month heath
status measures were most commonly missing due to ad-
ministrative reasons. The primary reasons for baseline
KCCQ and VAS to be missing were: “patient too sick”
(29% and 28%, respectively), and “patient consent not ob-
tained/patient not enrolled at time QoL instrument com-
pletion due” (30% and 28%, respectively). Besides missing
the entire 3-month follow-up visit, 3-month KCCQ and
VAS were most commonly missing because “coordinator
was too busy or forgot to administer QoL instrument”
(24% and 21%, respectively), “other” administrative rea-
sons (13% and 9%, respectively) and “reason not given”
(0.7% and 25%, respectively). Patients missing baseline
KCCQ data were more likely to be INTERMACS profile 1
at the time of implant, require IABP, mechanical ventila-
tion and dialysis prior to implant and to receive LVAD for
destination therapy (Additional file 1: Table S1).
Pre-operative health status scores and mortality and
rehospitalization
In unadjusted, IPW Kaplan-Meier analyses, pre-operative
KCCQ and VAS scores were not associated with mortality
or rehospitalization (Fig. 1). For mortality, the unadjusted
HR for lowest vs. highest score quartile of KCCQ was 1.09
(95% CI 0.84-1.41), and was 1.12 (0.85-1.49) for VAS. For
rehospitalization, the unadjusted HR for lowest vs. highest
score quartile of the KCCQ was 0.83 (95% CI 0.72-0.96),
and was 0.99 (0.85-1.16) for VAS. Results were similar
after adjusting for the variables in the HMIIRS (data not
shown). Pre-operative KCCQ and VAS did not add incre-
mental prognostic value when added to the variables in-
cluded in the HMIIRS (Table 2).
Three-month health status scores and mortality and
rehospitalization
In unadjusted, IPW Kaplan-Meier analysis, 3-month
KCCQ scores were significantly associated with mortality,
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which was primarily driven by the lowest health status
quartile (Q1; Fig. 2). Unadjusted HR (95% CI) for the low-
est vs. highest KCCQ score quartile was 2.17 (1.47-3.21),
and was 2.23 (1.49-3.34) after adjusting for the variables in
the HMIIRS. Three-month VAS scores, however, were not
associated with mortality (Fig. 2; Unadjusted HR (95% CI)
for lowest vs. highest score quartile was 1.43 (0.94-2.17)).
Three-month KCCQ and VAS were both statistically
associated with rehospitalization following LVAD im-
plantation (Fig. 2). The unadjusted HR (95% CI) for
Table 1 Patient characteristics by baseline KCCQ score quartile
Overall KCCQ Q1 KCCQ Q2 KCCQ Q3 KCCQ Q4
N 3836 552 558 556 559
KCCQ score median (IQR) 34.6 (21.4, 50.5)* 14.3 (9.6, 18.2) 28.1 (25.3, 31.5) 41.1 (37.5, 45.6) 63.8 (56.3, 74.5)
Age in yearsa
19-20 150 (4) 12 (2) 13 (2) 16 (3) 20 (4)
30-39 242 (6) 34 (6) 36 (7) 36 (7) 28 (5)
40-49 513 (13) 90 (16) 70 (13) 65 (12) 68 (12)
50-59 972 (25) 141 (26) 131 (24) 145 (26) 126 (23)
60-69 1330 (35) 189 (34) 207 (37) 177 (32) 212 (38)
70-79 597 (16) 80 (15) 97 (17) 111 (20) 101 (18)
≥80 32 (0.8) 6 (1) 4 (0.7) 6 (1) 4 (0.7)
Femaleb 807 (21) 148 (27) 133 (24) 97 (17) 82 (15)
INTERMACS profileb,§
1 (Critical cardiogenic shock) 500 (13) 66 (12) 27 (5) 23 (4) 26 (5)
2 (Progressive decline) 1361 (36) 237 (43) 197 (34) 188 (34) 195 (35)
3 (Stable but inotrope dependent) 1193 (31) 162 (29) 201 (36) 202 (36) 213 (38)
4 (Resting symptoms) 608 (16) 73 (12) 117 (21) 110 (20) 101 (18)
5 (Exertion intolerant) 112 (3) 7 (1) 14 (3) 25 (5) 13 (2)
6 (Exertion limited) 33 (0.9) 2 (0.4) 3 (0.5) 5 (0.9) 5 (0.9)
7 (Advanced NYHA III) 29 (0.8) 5 (0.9) 5 (0.9) 3 (0.5) 6 (1)
Device strategya
Bridge to transplant 788 (21) 97 (18) 112 (20) 102 (18) 141 (25)
Possible bridge to transplant 1326 (35) 169 (31) 178 (32) 183 (33) 167 (30)
Destination therapy 1,694 (44) 282 (51) 266 (48) 269 (48) 248 (4)
Other 28 (0.7) 4 (0.7) 2 (0.4) 2 (0.4) 3 (0.6)


























IABP¶ 918 (24) 146 (26) 89 (16) 86 (16) 71 (13)
Severe depressiond 98 (3) 23 (4) 21 (4) 12 (2) 7 (1)
Working for incomeb 572 (15) 49 (9) 72 (13) 71 (13) 109 (20)
6MWT† feetb 802 ± 412 607 ± 517 746 ± 374 843 ± 367 908 ± 366
Gait speed m/se 0.9 ± 0.8 0.6 ± 0.4 0.9 ± 1.1 0.9 ± 0.4 1.0 ± 1.0
VO2 max mL/kg/min
a 11.1 ± 3.7 10.6 ± 5.2 10.6 ± 2.4 11.4 ± 4.4 11.1 ± 2.7
All data are presented as N (%) or mean ± SD unless otherwise specified. All percents are rounded to the nearest whole number
* N = 2225
† 6 min Walk Test
¶ Intra-aortic balloon pump
§ Interagency Registry for Mechanically Assisted Circulatory Support
ap = NS; bp < 0.001 cp = 0.005; dp = 0.010 ep = 0.008
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lowest vs. highest score quartile of KCCQ was 1.34
(1.15-1.57), and was 1.35 (1.14-1.60) after adjusting for
the variables in the HMIIRS. For VAS, the unadjusted
HR (95% CI) was 1.24 (1.05-1.46), and was 1.20 (1.01-
1.43) after adjusting for the variables in the HMIIRS.
The 3-month KCCQ added incremental discriminatory
value for the outcome of mortality when added to the vari-
ables included in the HMIIRS (Table 2); VAS did not. Three-
month KCCQ and VAS scores did not add meaningful prog-
nostic value for the outcome of rehospitalization (Table 2).
Fig. 1 Unadjusted inverse propensity weighted Kaplan-Meier curves showing association between pre-operative (baseline) KCCQ and VAS with
mortality and hospitalization
Table 2 Incremental prognostic value of weighted health status over the HeartMate II Risk Score in predicting mortality and
rehospitalization after LVAD implantation
C-statistic (base clinical
score only)












0.60 0.61 0.51 0.50
Baseline EQ-5D VAS
(N = 2205)
0.60 0.60 0.51 0.52
3-month KCCQ
(N = 2060)
0.60 0.66 0.52 0.55
3-month EQ-5D VAS
(N = 2005)
0.59 0.60 0.52 0.54
Base clinical score was comprised of the variables included in the HeartMate II Risk Score [20] – age, albumin, creatinine, center volume, INR
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Discussion
In a large, prospective registry of patients receiving a
durable, continuous-flow LVAD in the usual care setting,
pre-operative health status was not associated with long-
term mortality or rehospitalization, and did not add in-
cremental discriminatory value to an existing validated
risk model. However, 3-month post-implant heart
failure-specific health status was associated with long-
term mortality, but less so with hospitalization. These
real-world results confirm our prior work in the clinical
trial setting, which also found no association between
baseline KCCQ and mortality following HeartMate II
implantation [15]. Taken together, these data suggest
that very poor pre-operative health status should not, in
and of itself, preclude LVAD implantation. Mechanical
circulatory support may represent a relatively unique
clinical situation, distinct from heart failure and other
cardiac surgeries, in which the intervention is so signifi-
cant that it renders pre-operative heart failure-specific
health status irrelevant. The current study also suggests
that serial measurements of heart failure-specific health
status following LVAD implantation may help inform
clinical decision-making; however, further work is
needed to identify the role health status might play in
guiding patients’ care once they have survived the acute,
post-operative period.
Current mortality risk prediction in the LVAD population
The HeartMate II Risk Score is one of the most com-
monly used risk tools for pre-LVAD assessment. It was
derived from a cohort of clinical trial patients who re-
ceived continuous-flow LVAD [20, 23], and has been val-
idated in additional populations showing variable
performance [3, 4, 17, 24]. When applied to 201
continuous-flow LVAD recipients at Columbia Univer-
sity Medical Center, the HeartMate II Risk Score had a
c-statistic of only 0.56 for 90-day mortality [3], but when
applied to 269 patients treated at Barnes-Jewish
Hospital, the c-statistic was 0.70 for 90-day mortality,
likely reflecting substantial differences in patient selec-
tion [4]. Loghmanpour et al. applied the HeartMate II
Risk Score to all patients in the INTERMACS database,
Fig. 2 Unadjusted inverse propensity weighted Kaplan-Meier curves showing association between 3-month KCCQ and VAS with mortality
and hospitalization
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and reported an overall c-statistic of 0.57 (90-day mor-
tality) and 0.60 (1-year mortality) [24], which is compar-
able to the results of the current study. The authors
then utilized the INTERMACS database to demonstrate
the significant promise of Bayesian analysis in predicting
mortality in patients undergoing LVAD placement; how-
ever, these methods requires further adaptation before
being easily applied in the clinical setting [24]. Given
these limitations, additional efforts are needed improve
prognostication in the LVAD population.
Mortality
The current study validated results from prior work
which demonstrated that pre-operative KCCQ scores
did not predict mortality or rehospitalization [15]. A po-
tential reason for this finding is that LVAD therapy often
improves patients’ heart failure so significantly that pre-
operative health status is no longer relevant. Moreover,
the long-term outcomes of LVAD patients are often dic-
tated by factors unrelated to the left ventricle (e.g.
stroke, right heart failure, infection, bleeding, renal dys-
function) [25]; indeed adverse events due to problems
with the LVAD itself are unlikely to be predicted by a
pre-operative patient-reported outcome such as health
status. Pre-operative health status may still aid in patient
selection for LVAD because those with much better
health status prior to LVAD will have less opportunity to
improve, and may not derive as much health status
benefit from treatment compared to those with poorer
pre-operative health status [26]. On the other hand, pa-
tients with poor pre-operative health status are more
likely to suffer death or low health status following
LVAD [22].
Interestingly, 3-month KCCQ was predictive of mor-
tality and added incremental prognostic value to the
base clinical model. Although overall health status im-
proves dramatically following LVAD [27], not all patients
will follow such a positive trajectory. Three-month
KCCQ may thus help identify patients unlikely to enjoy
the expected long-term benefit from their device due to
ongoing heart failure or complications of the therapy.
Prospective studies involving the serial measurement of
health status after LVAD may help inform decisions re-
garding interventions targeting health status, and guide
the timing of alternative treatment options, such as
transplant for eligible patients, or eventual transition to
palliative care.
Rehospitalization
In the current study, neither the base risk model nor
health status measures provided meaningful discrimin-
ation for rehospitalizations in patients with a continuous-
flow, durable LVAD. In general, hospitalizations for heart
failure are more challenging to predict than mortality
[28–32]. These problems may be magnified in the LVAD
population, as the LVAD itself introduces many new rea-
sons for why patients may be rehospitalized. Existing data
report remarkably high hospital readmission rates after
LVAD [33, 34]. The leading causes for hospital readmis-
sion in this population range from non-cardiac comorbidi-
ties [35], gastrointestinal bleeding [36], and device
component infection [37] to recurrent heart failure [38]
and progression of cardiac pathology [37]. The current
study represents the challenges inherent in attempting to
predict a very common outcome, and the need for further
study.
Future directions
Determining the full clinical utility of serial health
status measurements beyond 3 months after LVAD
will require further investigation. Ultimately, a novel
heath status tool tailored to the pre- and post-LVAD
populations, which incorporates broader concepts of
non-heart failure aspects of frailty,[39] may be the
most promising method for incorporating health sta-
tus into the care of patients both before and after
LVAD implantation. The design of such a tool will re-
quire careful consideration of the heterogeneous out-
comes patients with LVAD suffer, and may be most
successful as a series of tools designed to predict each
of the most common adverse outcomes following
LVAD implantation. Preliminary data by Grady et al.
describe the foundation for a novel health status tool
designed for the post-LVAD period [40].
Limitations
The current study must be interpreted with care in the
setting of its limitations. First, despite being the largest
source of both global and disease-specific health status
data in patients with LVAD, the INTERMACS registry is
missing health status data in a significant minority of pa-
tients. We tried to minimize selection bias by utilizing
IPW, a previously validated method for handling missing
health status data that may decrease bias by preferen-
tially weighting patients with health status measures
who look like patients with missing health status mea-
sures [21, 22]. Such techniques are only partial solutions;
however, despite these missing data concerns, INTER-
MACS has other significant advantages that make it one
of the best sources to investigate this question. Second,
we did not pursue analyses examining health status
scores collected beyond 3 months post-LVAD due to
very high rates of missing data at time points further
from implantation. Finally, we were not able to separate
device-related from patient-related causes of mortality
and rehospitalization; therefore, we may have underesti-
mated the predictive value of health status for patient-
related adverse outcomes.
Flint et al. BMC Cardiovascular Disorders  (2017) 17:78 Page 7 of 9
Conclusion
The current study builds upon prior work, confirming
the absence of an association between baseline health
status and mortality and hospitalization following LVAD
implantation, perhaps because LVAD is such a signifi-
cant intervention that it renders baseline health status ir-
relevant to these post-LVAD outcomes. However, in
patients who do survive the acute post-operative period,
heart failure-specific health status does hold prognostic
significance. Future studies should explore interventions
aimed at identifying patients with poor health status fol-
lowing LVAD, and focus on further refining the use of
post-operative health status measurements in the routine
clinical care of this complex patient population.
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